Objective. Does the addition of 600 mg rifampicin or 50 mg methotrexate improve pain relief after injection of the rheumatoid knee with 20 mg triamcinolone hexacetonide ( TH )?
I- steroid in rheumatoid arthritis (RA)
on systemic methotrexate or those intending pregnancy were excluded. has the appeal of fast-acting therapy, delivered to the inflamed area, and side-effects are infrequent. About
Baseline measures recorded were knee pain, knee pain disturbing sleep (five-point pain scales), effusion 15% do not respond [1] , there may be an inadequate response, and after repeated injections the duration of (three-point scale), tenderness (four-point scale), radiology (Larsen scale [10]), goniometry, knee cirbenefit frequently falls. Osmic acid has been used [2] , but alters the colour and other properties of cartilage cumference, palpable knee warmth, and microwave thermography of knees (a method of measuring joint [3] . Radioisotope injection requires experience in handling radioactive substances and appropriate facilities inflammation previously described elsewhere [11] ). Disease activity was assessed by the duration of mornare not widespread [4, 5] .
Methotrexate showed promise given as three 10 mg ing stiffness, erythrocyte sedimentation rate ( ESR) and C-reactive protein (CRP). Toxicity checks included full doses at 7 day intervals in psoriatic arthritis [6 ] , but this low dose was ineffective in RA and repeated blood count, liver function tests at days 0 and 10 in TH+ R and TH+M groups, and a 24 h methotrexate injections are time consuming and possibly more hazardous. Rifampicin analogues have proved popular blood assay. The primary end point was residual knee pain as assessed by the weekly self-administered fiveand are non-toxic [7] [8] [9] . Both compounds are readily available injectable preparations and form the basis of point pain scale. Clinical assessments at 0, 3 and 6 months were performed by the metrologist (AS ), who this study.
was unaware of the treatment.
PATIENTS AND METHODS
The injections were administered following aspiration to dryness using a sterile no-touch technique. Rheumatoid patients with a knee joint in exacerbation were randomized to receive 20 mg triamcinolone Statistical tests were non-parametric throughout. This study was approved by the Glasgow West hexacetonide ( TH ) alone, 20 mg TH with 600 mg rifampicin (TH+R) or 20 mg TH with 50 mg methoEthics Committee and all participants gave written informed consent. trexate ( TH+M ). Patients were required to have received stable systemic therapy for 3 months, to have RESULTS serum creatinine of <200 mmol/l, normal serum transaminases, normal platelet and white cell counts, and Eighty-two knees were treated (27 TH alone, 28 TH+M, 27 TH+R) and drop-outs are enumerated in no evidence of infection or previous adverse reaction to triamcinolone, rifampicin or methotrexate. Patients Table I . There was a trend to fewer repeat injections in the TH+R group. *P < 0.05, **P < 0.01, ***P < 0.001 for 3 month data compared with baseline ( Wilcoxon). There were no significant differences between groups.
by the area under the curve (AUC ) was better in the wave thermography index. Significant improvements were seen in effusion and range of movement at 3 TH+R group compared with TH alone (MannWhitney U, P = 0.039). Numbers assessed between 0 months in all three groups. This improvement in effusion persisted at 6 months in the TH+M and and 6 months were smaller ( TH group 15, TH+M 18, TH+R 17) and no significant differences in pain were TH+R groups. Knee circumference improved at 3 and 6 months in the TH+M and TH+R groups. These demonstrated. The median duration of improved pain scores following injection was 13.5 weeks for TH alone, observations were accompanied by significant improvements in the microwave thermography index in the 10 for TH+M and 19 for TH+R, but these differences failed to reach statistical significance. During the first TH alone and TH+R groups at 3 months. No significant changes occurred in systemic disease 3 months of observation, the percentage of pain-free patients was significantly greater in the TH+R group activity measurements (CRP, ESR, duration of morning stiffness). compared with either of the other groups ( x2, P < 0.001). The drop-outs and the diminishing benefits Adverse events were confined to the combination therapy groups. In the TH+M group, two patients of treatment made similar changes more difficult to demonstrate during the follow-up period from 13 to reported a flare of pain, in one case lasting 1 week and in the other 30 min. Two other patients had measurable 26 weeks. Table II shows changes in night pain, effusions, serum levels of methotrexate at 24 h and were treated with folinic acid 15 mg q.i.d. for 3 days. One of these tenderness, warmth, knee circumference and micro-patients suffered mouth ulcers at 10 days. In the but the flare after injection occurring in a significant proportion of patients needs to be prevented if at all TH+R group, 11 patients complained of post-injection pain which lasted longer than 24 h in eight patients possible. Rest and splintage may have something to offer. and at most 7 days. However, all of these patients reported improvement in pain for periods between 6 R and 26 weeks post-injection. No haematological or
